Metformin inhibits cervical cancer cell proliferation via decreased AMPK O-GlcNAcylation

다국어 초록 (Multilingual Abstract)

Metformin is a widely used drug for the treatment of type 2 diabetes. Antidiabetic drugs are also known to influence cancer progression, as high glucose levels affect both cancer and diabetes.
Metformin induces cell cycle arrest in cancer cells, but the underlying mechanism remains unclear in cervical cancer system. Here, we examined how metformin affects cell cycle arrest and apoptosis in cervical cancer cells. Western blot analysis showed that levels of O-linked Nacetylglucosamine (O-GlcNAc) and O-GlcNAc transferase (OGT) were increased in cervical cancer cells; these effects were reversed by metformin treatment. Immunoprecipitation analysis was used to examine the interplay between O-GlcNAcylation and phosphorylation in HeLa cells, revealing that metformin decreased O-GlcNAcylated AMP-activated protein kinase (AMPK) and increased levels of phospho-AMPK compared to untreated cells. These results were associated with decreased cell cycle arrest and apoptotic cell death in HeLa cells, as shown by flow cytometry.
Moreover, 6-diazo-5-oxo-L-norleucine (a glutamine fructose-6-phosphate aminotransferase inhibitor) or thiamet G (an O-GlcNAcase inhibitor) decreased or increased levels of O-GlcNAcylated AMPK, and increased or decreased levels of phosphorylated AMPK, respectively, suggesting that OGlcNAc modification affects AMPK activation. Of note, we found that metformin treatment of HeLa cells increased the levels of p21 and p27 (which are AMPK-dependent cell cycle inhibitors), leading to increased cell cycle arrest and apoptosis in HeLa cells compared to untreated cells. These findings suggest that metformin may serve as a useful antiproliferative drug in cervical cancer cells, with potential therapeutic benefit.

참고문헌 (Reference)

1 Richardson LC, "Therapy insight : influence of type 2 diabetes on the development, treatment and outcomes of cancer" 2 : 48-53, 2005

2 Shaw RJ, "The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin" 310 : 1642-1646, 2005

3 Zhou G, "Role of AMP-activated protein kinase in mechanism of metformin action" 108 : 1167-1174, 2001

4 Heckman-Stoddard BM, "Repurposing metformin for the prevention of cancer and cancer recurrence" 60 : 1639-1647, 2017

5 Kim M, "O-linked N-acetylglucosamine transferase promotes cervical cancer tumorigenesis through human papillomaviruses E6 and E7 oncogenes" 7 : 44596-44607, 2016

6 Ferrer CM, "O-GlcNAcylation in cancer biology : linking metabolism and signaling" 428 : 3282-3294, 2016

7 Coqueret O, "New roles for p21 and p27 cell-cycle inhibitors:a function for each cell compartment?" 13 : 65-70, 2003

8 Cai X, "Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo" 30 : 2449-2457, 2013

9 Zakikhani M, "Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells" 66 : 10269-10273, 2006

10 Queiroz EA, "Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells" 9 : e98207-, 2014

11 Evans JM, "Metformin and reduced risk of cancer in diabetic patients" 330 : 1304-1305, 2005

12 Rizos CV, "Metformin and cancer" 705 : 96-108, 2013

13 Foretz M, "Metformin : from mechanisms of action to therapies" 20 : 953-966, 2014

14 Liu Q, "Hyper-OGlcNAcylation of YB-1 affects Ser102 phosphorylation and promotes cell proliferation in hepatocellular carcinoma" 349 : 230-238, 2016

15 Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185countries" 68 : 394-424, 2018

16 Pham TD, "Erythropoietin inhibits chemotherapy-induced cell death and promotes a senescence-like state in leukemia cells" 10 : 22-, 2019

17 Li YY, "Drug repositioning for personalized medicine" 4 : 27-, 2012

18 Bullen JW, "Cross-talk between two essential nutrient-sensitive enzymes : O-GlcNAc transferase(OGT)and AMP-activated protein kinase(AMPK)" 289 : 10592-10606, 2014

19 Wang Z, "Cross-talk between GlcNAcylation and phosphorylation : site-specific phosphorylation dynamics in response to globally elevated OGlcNAc" 105 : 13793-13798, 2008

20 Hart GW, "Cross talk between O-GlcNAcylation and phosphorylation : roles in signaling, transcription, and chronic disease" 80 : 825-858, 2011

21 Ma Z, "Cancer metabolism and elevated OGlcNAc in oncogenic signaling" 289 : 34457-34465, 2014

22 Fu YL, "Antidiabetic drug metformin mitigates ovarian cancer SKOV3 cell growth by triggering G2/M cell cycle arrest and inhibition of m-TOR/PI3K/Akt signaling pathway" 21 : 1169-1175, 2017

23 Bond MR, "A little sugar goes a long way : the cell biology of O-GlcNAc" 208 : 869-880, 2015